Hetran 10 Tablet contains Vonoprazan 10 mg, a novel potassium-competitive acid blocker (P-CAB) indicated for the treatment of acid-related gastrointestinal disorders. Vonoprazan exerts its therapeutic effect by selectively and reversibly inhibiting the H+/K+-ATPase enzyme in gastric parietal cells, leading to a rapid and sustained suppression of gastric acid secretion. This mechanism provides superior acid control compared to traditional proton pump inhibitors (PPIs), with a faster onset of action and prolonged duration. Hetran 10 is primarily prescribed for the management of gastroesophageal reflux disease (GERD), peptic ulcer disease, and eradication of Helicobacter pylori infection when used in combination with appropriate antibiotics. The tablet is administered orally, typically once daily, with or without food, as directed by a healthcare professional. Clinical studies have demonstrated that Vonoprazan is well tolerated, with a safety profile comparable to existing acid-suppressive therapies. Common adverse effects may include headache, diarrhea, and abdominal discomfort, though these are generally mild and transient. Hetran 10 Tablet should be used with caution in patients with hepatic impairment and is contraindicated in individuals with known hypersensitivity to Vonoprazan or any excipients. Regular monitoring and adherence to prescribed dosage are essential to optimize therapeutic outcomes.